

Fampridine Newbury approved by the Swedish Health Authorities

Newbury Pharmaceuticals is pleased to announce the Marketing Authorization (MA) of Fampridine Newbury 10 mg prolonged-release tablets in Sweden as the first country in a Scandinavian registration procedure. Approvals in Norway and Denmark are expected to follow upon finalized national reviews.

“The approval of Fampridine Newbury is the 2nd product approved for the treatment of multiple sclerosis following the approval of Teriflunomide Newbury in October this year and it further shows our commitment within the field of Neurology. Multiple sclerosis is a serious life changing disease where the company aims to provide cost efficient alternatives to current treatments. Based on this positive progress, we will proceed to launch this product, within respective markets, as soon as regulatory exclusivities and patents allow us.” Says Mr. Lars Minor, CEO of Newbury.

Fampridine Newbury is a medicine used to improve walking ability in adults with multiple sclerosis (MS) who have a walking disability. It contains the active substance fampridine.

MS is a disease of the nerves, in which inflammation destroys the protective sheath around the nerves. Multiple sclerosis is characterized by immune-mediated inflammation and neurodegeneration. It is a disease of unknown aetiology.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Press Release
27 December 2022 10:00:00 CET



Attachments

[Fampridine Newbury approved by the Swedish Health Authorities](#)